

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrTaro-Deferiprone

Deferiprone Tablets
Tablets, 1000 mg, Oral

House Standard

Iron Chelating Agent

Taro Pharmaceuticals Inc.
130 East Drive, Brampton
ON, L6T1C1

Date of Initial Authorization:
NOV 13, 2024

Submission Control No: 283688

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

PART I: HEALTH PROFESSIONAL INFORMATION	4
1. INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2. CONTRAINDICATIONS.....	4
3. SERIOUS WARNINGS AND PRECAUTIONS BOX.....	5
4. DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations.....	5
4.2 Recommended Dose and Dosage Adjustment.....	6
4.4 Administration	7
4.5 Missed Dose.....	7
5. OVERDOSAGE	7
6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.....	7
7. WARNINGS AND PRECAUTIONS.....	8
7.1 Special Populations	11
7.1.1 Pregnant Women.....	11
7.1.2 Breast-feeding.....	11
7.1.3 Pediatrics	11
7.1.4 Geriatrics	11
8. ADVERSE REACTIONS.....	12
8.1 Adverse Reaction Overview	12
8.2 Clinical Trial Adverse Reactions.....	12
8.2.1 Clinical Trial Adverse Reactions – Pediatrics	17
8.3 Less Common Clinical Trial Adverse Reactions	17
8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics	17
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	17
8.5 Post-Market Adverse Reactions	17
9. DRUG INTERACTIONS	18
9.2 Drug Interactions Overview	18
9.3 Drug-Behaviour Interactions	18

9.4 Drug-Drug Interactions.....	18
9.5 Drug-Food Interactions	19
9.6 Drug-Herb Interactions	19
9.7 Drug-Laboratory Test Interactions	19
10. CLINICAL PHARMACOLOGY.....	20
10.1 Mechanism of Action	20
10.2 Pharmacodynamics.....	20
10.3 Pharmacokinetics.....	21
11. STORAGE, STABILITY AND DISPOSAL	24
12. SPECIAL HANDLING INSTRUCTIONS	24
PART II: SCIENTIFIC INFORMATION	25
13. PHARMACEUTICAL INFORMATION	25
14. CLINICAL TRIALS	25
14.1 Clinical Trials by Indication.....	25
14.3 Comparative Bioavailability Studies	30
15. MICROBIOLOGY.....	31
16. NON-CLINICAL TOXICOLOGY.....	31
17. SUPPORTING PRODUCT MONOGRAPHS	33
PATIENT MEDICATION INFORMATION	34

PART I: HEALTH PROFESSIONAL INFORMATION

1. INDICATIONS

Taro-Deferiprone (deferiprone) is indicated for:

- the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
- the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

Taro-Deferiprone is available only through a controlled distribution program called **Taro Cares**. Under this program, only physicians and pharmacists registered with the program are able to prescribe and dispense the product. In addition, Taro-Deferiprone can be dispensed only to patients who are registered with and meet the conditions of the **Taro Cares** program. Please call 1-800-268-1975 or log onto tarocares.ca.

1.1 Pediatrics

Pediatrics (1-15 years of age): Based on the data submitted to and reviewed by Health Canada, the safety and efficacy of deferiprone in pediatric patients (1-15 years of age) with thalassemia syndromes and iron overload has been established. Therefore, Health Canada has authorized an indication for pediatric patients of 1-15 years of age with thalassemia syndromes and iron overload. In clinical trials, pediatric patients experienced a higher frequency of decreased neutrophil counts than older patients (see [7.1.3 Pediatrics](#)).

Pediatrics (3-16 years of age): Based on the data submitted to and reviewed by Health Canada, the safety and efficacy of deferiprone in pediatric patients (3-16 years of age) with sickle cell disease or other anemias and iron overload has been established. Therefore, Health Canada has authorized an indication for pediatric patients of 3-16 years of age with sickle cell disease or other anemias and iron overload. In clinical trials, pediatric patients experienced a higher frequency of abdominal pain, decreased neutrophil counts, bone pain and oropharyngeal pain than older patients (see [7.1.3 Pediatrics](#)).

1.2 Geriatrics

There are limited data on the use of deferiprone in this population.

2. CONTRAINDICATIONS

- Deferiprone is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, COMPOSITION AND PACKAGING](#).

- Deferiprone is contraindicated in women who are pregnant and/or breastfeeding (see [7.1.1 Pregnant Women](#) and [7.1.2 Breast-feeding](#)).
- Deferiprone is contraindicated in patients who have baseline severe neutropenia (absolute neutrophil count $< 0.5 \times 10^9/L$) (see [7 WARNINGS AND PRECAUTIONS, Hematologic](#)).

3. SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- Deferiprone can cause agranulocytosis/severe neutropenia that may lead to serious and life-threatening infections. Neutropenia may precede the development of agranulocytosis (see [8 ADVERSE REACTIONS](#)).
 - Measure the absolute neutrophil count (ANC) before starting Taro-Deferiprone and monitor the ANC weekly on therapy (see [7 WARNINGS AND PRECAUTIONS, Hematologic](#) and [8 ADVERSE REACTIONS](#) sections). Interrupt Taro-Deferiprone therapy if neutropenia develops.
 - Interrupt Taro-Deferiprone therapy if infection develops and monitor the ANC more frequently (see [7 WARNINGS AND PRECAUTIONS, Hematologic](#)).
 - Advise patients taking Taro-Deferiprone to immediately seek medical help and present their wallet card if experiencing any symptoms indicative of infection (see [7 WARNINGS AND PRECAUTIONS, Hematologic](#)).

4. DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- Taro-Deferiprone is given three times a day (see [4.2 Dosage and Administration](#))
- The effect of Taro-Deferiprone in decreasing the body iron load is directly influenced by the dose and the degree of iron overload (pre-existing iron load and amount of iron input (transfusional iron and gastrointestinal iron absorption)).
- The long-term effectiveness of Taro-Deferiprone in controlling body iron load should be evaluated on a regular basis. It is recommended to monitor serum ferritin concentrations every two to three months and to monitor liver and cardiac iron concentrations annually, or as clinically indicated.
- Dose adjustments should be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of iron burden). Reduction in dose of Taro-Deferiprone should be considered if serum ferritin measurements approach normal.
- In patients who develop gastrointestinal upset, such as nausea, vomiting and abdominal pain, the dose of Taro-Deferiprone should be decreased for one to two weeks.

4.2 Recommended Dose and Dosage Adjustment

The recommended starting dosage of Taro-Deferiprone for adults and pediatric patients is 75 mg/kg actual body weight/day orally. The maximum dosage is 100 mg/kg actual body weight/day orally.

Recommended Dosage for Taro-Deferiprone (three times a day)

For Taro-Deferiprone 1000 mg tablets taken three times a day, dose per kilogram body weight should be calculated to the nearest half tablet. To obtain a dose of about 75 mg/kg/day, use the number of tablets suggested in the following tables for the body weight of the patient.

Table 1: Dosage table for Taro-Deferiprone 1000 mg tablets

Body weight (kg)	Total daily dose (mg)	Number of 1 000 mg tablets*		
		Morning	Midday	Evening
20	1 500	0.5	0.5	0.5
30	2 250	1.0	0.5	1.0
40	3 000	1.0	1.0	1.0
50	3 750	1.5	1.0	1.5
60	4 500	1.5	1.5	1.5
70	5 250	2.0	1.5	2.0
80	6 000	2.0	2.0	2.0
90	6 750	2.5	2.0	2.5

*rounded to nearest half tablet

Dose Modifications for Patients with Hepatic Impairment

No adjustment of the Taro-Deferiprone dosage regimen is recommended in patients with mildly (Child-Pugh Class A) or moderately (Child-Pugh Class B) impaired hepatic function. There are no data in patients with severe (Child-Pugh Class C) hepatic impairment. Liver enzymes should be carefully monitored in this patient population during Taro-Deferiprone therapy. If there is evidence of deterioration in hepatic function, discontinuation of Taro-Deferiprone therapy should be considered (see [7 WARNINGS AND PRECAUTIONS](#) and [10 CLINICAL PHARMACOLOGY](#)).

Dose Modification for Patients with Renal Impairment

No adjustment of Taro-Deferiprone dosage is recommended in patients with mild, moderate or severe renal impairment. There are no data in patients with end-stage renal disease on dialysis.

4.4 Administration

Taro-Deferiprone can be taken with or without food. Taking Taro-Deferiprone with meals may reduce nausea.

Allow at least a 4-hour interval between Taro-Deferiprone and other medications or supplements containing polyvalent cations such as iron, aluminum or zinc (see [9 DRUG INTERACTIONS](#)).

4.5 Missed Dose

If a dose of this medicine has been missed, it should be taken as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not catch up or double doses.

5. OVERDOSAGE

There is no specific antidote to deferiprone overdose.

Prolonged overdosing (at approximately 2.5 times the maximum recommended dose) has been reported to be associated with adverse neurological effects, such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, abnormal hand movements and axial hypotonia (see [7 WARNINGS AND PRECAUTIONS](#)). The neurological disorders regressed after deferiprone discontinuation.

For management of a suspected drug overdose, contact your regional poison control centre.

6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 2: Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
oral	Tablets / 1000 mg	methylcellulose, crospovidone type B, magnesium stearate, purified water, white film coating (hypromellose 2910, copovidone K25-31, polydextrose, macrogol/PEG 3350, medium chain triglycerides, titanium dioxide)

Film coated white oval shaped tablet debossed with “T” score “1K” on one side and plain on the other. The tablets can be broken in half along the score. Each 1000 mg tablet contains 1000 mg deferiprone. Supplied in bottles of 50 tablets.

7. WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

Carcinogenesis and Mutagenesis

Please refer to the animal data presented in [16 NON-CLINICAL TOXICOLOGY](#).

Hematologic

Agranulocytosis/Severe Neutropenia

Deferiprone can cause agranulocytosis/severe neutropenia that may lead to serious and life-threatening infections. Agranulocytosis may be preceded by neutropenia (see ADVERSE REACTIONS). The mechanism of deferiprone-associated agranulocytosis is unknown.

In the pooled safety database, agranulocytosis/severe neutropenia was reported in 1.7% of patients. Agranulocytosis and neutropenia usually resolve upon discontinuation of deferiprone, but there have been post-marketing reports of agranulocytosis leading to death. Suggested management of cases of neutropenia and agranulocytosis is outlined below. It is recommended that such a management protocol be in place prior to initiating any patient on Taro-Deferiprone treatment.

Patients should avoid other medicinal products known to be associated with neutropenia or agranulocytosis. Measure the absolute neutrophil count (ANC) before starting Taro-Deferiprone therapy and monitor the ANC weekly on therapy.

Advise the patient to present the wallet card when seeing any healthcare professional for any reason as patients should avoid other medicinal products known to be associated with neutropenia or agranulocytosis.

For infection

Interrupt Taro-Deferiprone therapy if infection develops and monitor the ANC more frequently.

If patients taking Taro-Deferiprone experience any symptoms indicative of infection, advise them to immediately interrupt therapy, seek medical help and present the wallet card to the healthcare professional.

For neutropenia (ANC < $1.5 \times 10^9/L$ and $\geq 0.5 \times 10^9/L$):

Interrupt Taro-Deferiprone therapy if neutropenia develops.

Instruct the patient to immediately discontinue Taro-Deferiprone and all other medications with a potential to cause neutropenia. The patient should be advised to limit contact with other individuals in order to reduce the risk of infection.

Obtain a complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count daily until recovery (ANC $\geq 1.5 \times 10^9/L$). Should any evidence of infection develop concurrently with the neutropenia, the appropriate cultures and diagnostic procedures should be performed and an appropriate therapeutic regimen instituted.

For agranulocytosis/severe neutropenia ($ANC < 0.5 \times 10^9/L$):

Follow the above guidelines for neutropenia and if clinically indicated, admit patient to the hospital and institute other management as clinically appropriate.

Limited information is available regarding rechallenge in patients who experienced deferiprone-induced neutropenia or agranulocytosis. Deferiprone therapy has been resumed in 31 patients (3 from clinical trials and 28 in post-marketing surveillance) who previously experienced deferiprone-induced agranulocytosis, and agranulocytosis recurred in 14 (45%) of these patients. In clinical trials, rechallenge in patients with moderate or severe neutropenia was not permitted by protocol. Resumption of Taro-Deferiprone in patients who develop agranulocytosis is not recommended.

Patients with Diamond-Blackfan anemia, an unauthorized indication, may be at greater risk of deferiprone-induced agranulocytosis/severe neutropenia. Taro-Deferiprone therapy is not recommended in patients with Diamond-Blackfan anemia.

Hepatic/Biliary/Pancreatic

In the pooled safety database, 7.5% of 642 patients treated with deferiprone developed increased serum alanine aminotransferase (ALT) values. The majority of these events were transient. Four (0.6%) deferiprone-treated patients discontinued the drug due to increased serum ALT levels and 1 (0.2%) due to an increase in both ALT and aspartate aminotransferase (AST) values.

Serum ALT values should be monitored periodically during therapy with Taro-Deferiprone and interruption of therapy should be considered if there is a persistent increase in ALT levels.

Hepatic Impairment

A serious adverse event of acute liver and renal injury was seen in one subject with moderate hepatic impairment. No adjustment of the Taro-Deferiprone dosage regimen is required in patients with mildly or moderately impaired hepatic function. Liver enzymes should be carefully monitored in this patient population during Taro-Deferiprone therapy. If there is evidence of deterioration in hepatic function, discontinuation of Taro-Deferiprone should be considered (see [4.2 Dosage Recommendation](#)).

Immune

Given that deferiprone can be associated with neutropenia and agranulocytosis, therapy in immune-compromised patients should not be initiated unless potential benefits outweigh potential risks.

Interrupt Taro-Deferiprone therapy if infection develops and monitor the ANC more frequently.

Advise patients taking Taro-Deferiprone to immediately interrupt therapy and report to their physician if they experience any symptoms indicative of infection.

Monitoring and Laboratory Tests

The long-term effectiveness of Taro-Deferiprone in controlling body iron load should be evaluated on a regular basis. It is recommended to monitor serum ferritin concentrations every two to three months and to monitor liver and cardiac iron concentrations annually, or as clinically indicated (see [4 DOSAGE AND ADMINISTRATION](#)).

Absolute Neutrophil Counts

The absolute neutrophil count (ANC) should be measured before starting Taro-Deferiprone therapy and monitored weekly on therapy (see [2 CONTRAINDICATIONS](#) and [7 WARNINGS AND PRECAUTIONS](#), [Hematologic](#) section above).

Hepatic function

Hepatic status should be evaluated prior to initiating Taro-Deferiprone treatment. Serum ALT values should be monitored periodically during therapy with Taro-Deferiprone. In patients with hepatic impairment, hepatic enzymes should be monitored periodically. Special care must be taken to ensure that iron chelation in patients with hepatitis C is optimal. In these patients careful monitoring of liver enzymes and of liver histology is recommended.

Plasma Zinc concentration

Monitoring of plasma Zn²⁺ concentration, and supplementation in case of a deficiency, is recommended.

Neurologic

Neurological disorders such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, abnormal hand movements and axial hypotonia, have been observed in two children treated for several months with approximately 2.5 times the maximum recommended dose, but have also been observed with standard doses of deferiprone. The neurological disorders regressed after deferiprone discontinuation ([5 OVERDOSAGE](#)).

Reproductive Health: Female and Male Potential

Women of childbearing potential must be advised to avoid pregnancy. These women should be advised to take highly effective contraceptive measures during treatment with Taro-Deferiprone and for at least six months after the last dose. Women of childbearing potential should immediately stop taking Taro-Deferiprone if they become pregnant or plan to become pregnant (See [2 CONTRAINDICATIONS](#) and [7.1.1 Pregnant Women](#)). Males with female partners of reproductive potential should use effective contraception during treatment with Taro-Deferiprone and for at least three months after the last dose.

- **Fertility**

Deferiprone had no significant effects on fertility and reproductive performance in non-iron-loaded male and female rats dosed orally at ≤ 75 mg/kg *bid* prior to and through mating (males) or through early gestation (females) (see [16 NON-CLINICAL TOXICOLOGY](#)).

7.1 Special Populations

7.1.1 Pregnant Women

Deferiprone is contraindicated in pregnancy (see [2 CONTRAINDICATIONS](#)). No studies in pregnant women have been conducted, and relevant data from clinical use are limited. In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal death and malformations at doses lower than equivalent human clinical doses (see [16 NON-CLINICAL TOXICOLOGY](#)).

7.1.2 Breast-feeding

Deferiprone is contraindicated in nursing women. No studies have been conducted to determine the extent of deferiprone excretion in human milk. No prenatal and postnatal reproductive studies have been conducted in animals. If treatment is unavoidable, breast-feeding must be stopped.

7.1.3 Pediatrics

Deferiprone has been studied in 222 pediatric patients with thalassemia syndromes and iron overload participating in clinical trials, including 61 children less than 6 years old. A higher rate of the following adverse events were reported in children less than 6 years old than in older patients: decreased neutrophil count (17 (27.9%) vs 40 (6.9%)), neutropenia (7 (11.5%) vs 36 (6.2%)), increased alanine aminotransferase (10 (16.4%) vs 46 (7.9%)), and agranulocytosis (2 (3.3%) vs 9 (1.5%)).

Deferiprone has been studied in 113 pediatric patients with sickle cell disease and other anemias and iron overload participating in clinical trials. The age of these patients ranged from 3 to 16 years old (66 patients were 3 to <12 years, 47 patients were 12 to 16 years). Seventy-seven percent of these patients had sickle cell disease. A higher rate of the following adverse events were reported in children than in adults: abdominal pain (41 (36.3%) vs 16 (19.3%)), decreased neutrophil count (20 (17.7%) vs 4 (4.8%)), bone pain (41 (36.3%) vs 17 (20.5%)), and oropharyngeal pain (23 (20.4%) vs 8 (9.6%)).

7.1.4 Geriatrics

Clinical studies of deferiprone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

8. ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The most common adverse reactions reported during therapy with deferiprone in clinical trials were chromaturia, nausea, abdominal pain, vomiting, arthralgia, alanine aminotransferase increased, and neutropenia. The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis/severe neutropenia, defined as an absolute neutrophil count of less than $0.5 \times 10^9/L$, which occurred in approximately 2% of patients. Less severe episodes of neutropenia were reported in approximately 6% of patients (see [7 WARNINGS AND PRECAUTIONS](#)). Arthropathies (including arthralgia, arthritis, and arthropathy) led to deferiprone discontinuation in 1.9% of patients. Gastrointestinal symptoms led to the discontinuation of deferiprone therapy in 1.6% of patients. Chromaturia (reddish/brown discolouration of the urine) is a result of the excretion of deferiprone-iron complex in the urine; it is an expected effect of deferiprone therapy and it is not harmful.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Thalassemia Syndromes

Study LA16-0102

Adverse events described in Table 3 below reflect the safety data from Study LA16-0102, a randomized, controlled trial in which 29 patients who were treated with deferiprone for a median duration of 359 days were compared to 32 patients treated with deferoxamine for a median duration of treatment of 365 days. Therapy with deferiprone was initiated at 75 mg/kg/d and was gradually increased to 100 mg/kg/d over an approximately 8-week period. The mean dose of deferiprone during the study was 92 mg/kg/d. Adverse events reported at $\geq 10\%$ incidence in either the deferiprone or deferoxamine arms are presented.

Table 3: Adverse events reported in $\geq 10\%$ in either the deferiprone or deferoxamine arms in Study LA16-0102

	Deferiprone n subjects exposed=29	Deferoxamine n subjects exposed=32
System Organ Class Preferred Term	N subjects (%)	N subjects (%)
Eye disorders	3 (10)	4 (13)
Conjunctivitis	3 (10)	4 (13)
Gastrointestinal disorders	20 (69)	14 (44)
Nausea	11 (38)	0 (0)

	Deferiprone n subjects exposed=29	Deferoxamine n subjects exposed=32
System Organ Class Preferred Term	N subjects (%)	N subjects (%)
Abdominal pain upper	9 (31)	3 (9)
Vomiting	9 (31)	5 (16)
Diarrhea	7 (24)	2 (6)
Abdominal discomfort	4 (14)	1 (3)
Abdominal pain	4 (14)	4 (13)
Epigastric discomfort	4 (14)	3 (9)
Eructation	4 (14)	0 (0)
Toothache	3 (10)	4 (13)
General disorders and administration site conditions	5 (17)	4 (13)
Asthenia	3 (10)	4 (13)
Chest pain	3 (10)	0 (0)
Infections and infestations	19 (66)	22 (69)
Pharyngitis	7 (24)	12 (38)
Rhinitis	6 (21)	5 (16)
Viral infection	6 (21)	9 (28)
Gastroenteritis	3 (10)	5 (16)
Tooth abscess	3 (10)	2 (6)
Vaginal infection	3 (10)	2 (6)
Nasopharyngitis	2 (7)	7 (22)
Injury, poisoning and procedural complications	4 (14)	7 (22)
Transfusion reaction	4 (14)	4 (13)
Allergic transfusion reaction	0 (0)	4 (13)
Investigations	21 (72)	16 (50)
Weight increased	12 (41)	6 (19)
Alanine aminotransferase increased	11 (38)	5 (16)
Aspartate aminotransferase increased	6 (21)	1 (3)
Electrocardiogram t wave inversion	6 (21)	0 (0)
White blood cell count decreased	5 (17)	6 (19)
Gamma-glutamyltransferase increased	4 (14)	2 (6)
Electrocardiogram repolarisation abnormality	3 (10)	0 (0)
Neutrophil count decreased	1 (3)	4 (13)
Weight decreased	1 (3)	9 (28)
Metabolism and nutrition disorders	9 (31)	0 (0)
Increased appetite	9 (31)	0 (0)

	Deferiprone n subjects exposed=29	Deferoxamine n subjects exposed=32
System Organ Class Preferred Term	N subjects (%)	N subjects (%)
Musculoskeletal and connective tissue disorders	16 (55)	17 (53)
Back pain	12 (41)	15 (47)
Arthralgia	8 (28)	4 (13)
Myalgia	3 (10)	2 (6)
Nervous system disorders	15 (52)	16 (50)
Headache	14 (48)	16 (50)
Dizziness	2 (7)	4 (13)
Reproductive system and breast disorders	3 (10)	3 (9)
Dysmenorrhea	3 (10)	3 (9)
Respiratory, thoracic and mediastinal disorders	0 (0)	6 (19)
Cough	0 (0)	6 (19)
Skin and subcutaneous tissue disorders	5 (17)	3 (9)
Dermatitis contact	3 (10)	1 (3)
Urticaria	3 (10)	2 (6)

- Treatment Emergent Adverse Events are coded with MedDRA Dictionary Version 13.0.

Study LA36-0310

LA36-0310 was prospectively designed as a pooled analysis of pre-existing data from studies that evaluated the efficacy of deferiprone. A safety evaluation was not included in the LA36-0310 analysis.

Pooled Safety Database

The safety of deferiprone has been evaluated from a pooled safety population of 642 deferiprone-treated patients who participated in 11 single arm or active-controlled clinical studies for which safety data was collected.

Table 4 below lists the adverse drug reactions that occurred in at least 1% of patients in the deferiprone pooled safety database.

Table 4: Adverse drug reactions reported in $\geq 1\%$ of deferiprone-treated patients from pooled safety database

Body System Preferred Term	(N=642) % Patients
BLOOD AND LYMPHATIC SYSTEM DISORDERS	
Neutropenia	6.2
Agranulocytosis/severe neutropenia	1.7
GASTROINTESTINAL DISORDERS	
Nausea	12.6
Abdominal pain/discomfort	10.4
Vomiting	9.8
Diarrhea	3.0
Dyspepsia	2.0
INVESTIGATIONS	
Alanine aminotransferase increased	7.5
Neutrophil count decreased	7.3
Weight increased	1.9
Aspartate aminotransferase increased	1.2
METABOLISM AND NUTRITION DISORDERS	
Increased appetite	4.0
Decreased appetite	1.1
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	
Arthralgia	9.8
Back pain	2.0
Pain in extremity	1.9
Arthropathy	1.4
NERVOUS SYSTEM DISORDERS	
Headache	2.5
URINARY DISORDERS	
Chromaturia	14.6

Sickle Cell Disease or other Anemias

The safety of deferiprone has been evaluated in 196 patients with sickle cell disease or other anemias who participated in studies LA38-0411 and LA38-EXT.

Table 5 below lists the adverse events that occurred in at least 5% of patients treated with deferiprone in LA38-0411 subjects with sickle cell disease or other anemias.

Table 5: Adverse events reported in ≥5% of deferiprone-treated patients with sickle cell disease or other anemias (Study LA38-0411)

Body System Adverse Reaction	DEFERIPRONE (N=152) % Patients	DEFEROXAMINE (N=76) % Patients
BLOOD AND LYMPHATIC SYSTEM DISORDERS		
Sickle cell anemia with crisis	17	13
GASTROINTESTINAL DISORDERS		
Abdominal pain*	26	13
Vomiting	19	11
Nausea	7	9
Diarrhea	5	8
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS		
Pyrexia	28	33
Pain	5	4
INFECTIONS AND INFESTATIONS		
Nasopharyngitis	9	12
Upper respiratory tract infection	5	3
INVESTIGATIONS		
Alanine aminotransferase increased	12	0
Aspartate aminotransferase increased	11	0
Neutrophil count decreased	8	4
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS		
Bone pain	25	34
Pain in extremity	18	15
Back pain	13	18
Arthralgia	10	8
NERVOUS SYSTEM DISORDERS		
Headache	20	13
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS		
Oropharyngeal pain	10	15
Cough	8	15

*Grouped term

Patients who completed the 1-year non-inferiority study LA38-0411 were offered the opportunity to take part in the 2-year extension study LA38-EXT. Those who had been treated with deferiprone continued to receive it (N=89), while those who had been treated with deferoxamine were switched to deferiprone (N=45). The long-term safety profile of deferiprone in patients with sickle cell disease and other transfusion dependent anemias is consistent with above safety profile. Agranulocytosis rate, the deferiprone side effect of greatest concern, is comparable to the rate of between 1% and 2% seen in thalassemia patients.

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

Deferiprone has been studied in 222 pediatric patients with thalassemia syndromes and iron overload participating in clinical trials, including 61 children less than 6 years old. A higher rate of the following adverse events were reported in children less than 6 years old than in older patients: decreased neutrophil count (17 (27.9%) vs 40 (6.9%)), neutropenia (7 (11.5%) vs 36 (6.2%)), increased alanine aminotransferase (10 (16.4%) vs 46 (7.9%)), and agranulocytosis (2 (3.3%) vs 9 (1.5%)).

Deferiprone has been studied in 113 pediatric patients with sickle cell disease and other anemias and iron overload participating in clinical trials. The age of these patients ranged from 3 to 16 years old (66 patients were 3 to <12 years, 47 patients were 12 to 16 years). Seventy-seven percent of these patients had sickle cell disease. A higher rate of the following adverse events were reported in children than in adults: abdominal pain (41 (36.3%) vs 16 (19.3%)), decreased neutrophil count (20 (17.7%) vs 4 (4.8%)), bone pain (41 (36.3%) vs 17 (20.5%)), and oropharyngeal pain (23 (20.4%) vs 8 (9.6%)).

8.3 Less Common Clinical Trial Adverse Reactions

Not applicable.

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics

Not applicable.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Not applicable.

8.5 Post-Market Adverse Reactions

The following additional adverse reactions have been reported in patients receiving deferiprone. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: agranulocytosis, including some fatal cases, thrombocytosis, pancytopenia.

Cardiac disorders: atrial fibrillation, cardiac failure.

Congenital, familial and genetic disorders: hypospadias, congenital anomaly.

Eye disorders: diplopia, papilledema, retinal toxicity.

Gastrointestinal disorders: enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.

General disorders and administration site conditions: chills, pyrexia, edema peripheral, multi-organ failure.

Hepatobiliary disorders: jaundice, hepatomegaly.

Immune system disorders: anaphylactic shock, hypersensitivity.

Infections and infestations: cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.

Investigations: blood bilirubin increased, blood creatinine phosphokinase increased.

Metabolism and nutrition disorders: metabolic acidosis, dehydration.

Musculoskeletal and connective tissue disorders: myositis, chondropathy, trismus.

Nervous system disorders: cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.

Psychiatric disorders: bruxism, depression, obsessive-compulsive disorder.

Renal disorders: glycosuria, hemoglobinuria.

Respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.

Skin, subcutaneous tissue disorders: hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schönlein purpura.

Vascular disorders: hypotension, hypertension.

9. DRUG INTERACTIONS

9.2 Drug Interactions Overview

In vitro, deferiprone up to 400 µM (56 µg/mL) did not inhibit any of the CYP450 enzymes tested, i.e., CYP3A4, 2D6, 2C9, 1A2, 2E1 and 1A1. Drug-drug interactions between deferiprone and medications metabolized by cytochrome P450 enzymes are unlikely to occur.

9.3 Drug-Behaviour Interactions

Interactions with behavioural risks have not been established

9.4 Drug-Drug Interactions

Drugs associated with neutropenia or agranulocytosis

Avoid concomitant use of Taro-Deferiprone with other drugs known to be associated with neutropenia or agranulocytosis (see [7 WARNINGS AND PRECAUTIONS](#)).

UDP-glucuronosyltransferases (UGTs) inhibitors and inducers

Deferiprone is primarily eliminated via metabolism to the 3-*O*-glucuronide. *In vitro* studies suggest that glucuronidation is catalyzed primarily by UDP glucuronosyltransferase 1A6. Deferiprone exposure may be increased in the presence of a UGT1A6 inhibitor. An *in vitro* study showed a dose-dependent inhibition of deferiprone glucuronide formation by acetaminophen (up to 33%) in human UGT1A6 Supersome incubations. Deferiprone glucuronide formation was increased by omeprazole (up to 43%) in human hepatocyte cultures.

However, the clinical significance of coadministration of deferiprone with a UGT1A6 inhibitor (e.g., acetaminophen, probenecid, and valproic acid) or an inducer (e.g., omeprazole, phenobarbital, and carbamazepine) has not been determined. Closely monitor patients for adverse reactions that may require downward dose titration or interruption when Taro-Deferiprone is concomitantly administered with a UGT1A6 inhibitor.

Polyvalent cations

Concurrent use of deferiprone with mineral supplements and antacids that contain polyvalent cations has not been studied. Since deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc), the concurrent use may result in reduced absorption of deferiprone and mineral supplements. It is recommended to allow at least a 4-hour interval between taking Taro-Deferiprone and other medications (e.g., antacids), or supplements containing these polyvalent cations (see [4 DOSAGE AND ADMINISTRATION](#)).

9.5 Drug-Food Interactions

Administration of deferiprone tablets with food in healthy volunteers decreased the C_{max} of deferiprone by 38% and the AUC by 10% (see [10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics](#)).

Taro-Deferiprone can be taken with or without food. Taking Taro-Deferiprone with meals may reduce nausea.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10. CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Deferiprone is an orally active, bidentate iron(III) chelating agent with an affinity for ferric ions (iron III), binding them in neutral 3:1 (deferiprone:iron) complexes. Deferiprone has a lower binding affinity for metal ions such as copper, aluminum, zinc and ferrous ions (iron II) than for ferric ions.

10.2 Pharmacodynamics

The amount of deferiprone-induced iron excretion from the body is related to the dose of deferiprone, and is also influenced by the pre-existing iron load.

Primary pharmacodynamics

Deferiprone has a high affinity for iron(III) ($pFe^{+3} = 19.4$) and preferentially binds trivalent cations over divalent in the order of affinity: Fe(III) > Al(III) > Cu(II) > Zn(II) > Fe(II).

A clinical study in thalassemia patients with iron overload demonstrated a dose-response relationship for deferiprone and 24-h urinary iron excretion at daily doses of between 25 and 100 mg/kg. Iron balance studies in thalassemia patients with iron overload demonstrated a dose-response relationship for deferiprone and iron excretion at doses of between 17 and 33 mg/kg three times daily. Deferiprone at doses of 25 mg/kg given three times daily promoted iron excretion sufficient to achieve negative iron balance or to neutralize the continued transfusional iron loading in the majority of transfusion-dependent patients.

Secondary Pharmacodynamics

Secondary pharmacodynamic effects of deferiprone may occur due to its binding of labile iron or other biologically important cations (e.g., Zn^{2+} , Cu^{2+}), which could result in depletion of cation pools required for metalloenzyme function. *In vivo* or *in vitro* studies revealed that deferiprone can inhibit the activity of the following enzymes at doses relevant to clinical exposures: tyrosine hydroxylase, tryptophan hydroxylase, hypoxia-inducible factor prolyl hydroxylase, ribonucleotide reductase, deoxyhypusine hydroxylase, catechol-*O*-methyl transferase, soybean LOX-1 (as a model for human 5-lipoxygenase) and heme iron-dependent cyclooxygenase. Inhibition of the non-heme iron-containing metalloenzyme ribonucleotide reductase is consistent with findings of clastogenicity, teratogenicity, and atrophy of proliferating tissues. Deferiprone was shown to reduce zinc levels and induce apoptosis in murine thymocytes.

Cardiac Electrophysiology, Electrocardiography

A study was conducted to evaluate the effect of single therapeutic (33 mg/kg) and suprathreshold (50 mg/kg) oral doses of deferiprone 500 mg tablets on the cardiac QT and QTc interval duration in healthy subjects. The upper bound of the 95% one-sided confidence interval for the least-squares mean difference in QTcF between placebo and either dose was < 10 milliseconds (ms) at all post-dose time points. The largest mean differences in QTcF from placebo were recorded at the 2 h time point and were 3.0 ms (95% one-sided UCL: 5.0 ms) for

the 33 mg/kg dose and 5.2 ms (95% one-sided UCL: 7.2 ms) for the 50 mg/kg dose. Deferiprone was concluded to produce no significant prolongation of the QTc interval.

The 33 mg/kg dose of deferiprone was associated with statistically significant positive mean differences from placebo in heart rate, with a maximum mean difference of 4.9 (beats per minute) bpm (90% CI 3.2, 6.6) at 3 h. The 50 mg/kg dose of deferiprone was associated with statistically significant increases in heart rate from 2-10 h post-dosing, inclusive, with a maximum mean difference from placebo of 12.9 bpm (90% CI 10.8, 15.0) at 4 h.

The 33 mg/kg dose of deferiprone was associated with statistically significant decreases in systolic blood pressure at 0.6 h and 2 h, with a maximal mean difference from placebo of 3.0 mmHg (90% CI -5.1, -0.9). The 50 mg/kg dose of deferiprone was associated with statistically significant decreases in systolic blood pressure from 1 to 6 h, inclusive, with a maximum mean difference from placebo of -4.4 mmHg (90% CI -6.6, -2.1) at 1 h post-dosing.

The 33 mg/kg dose of deferiprone was associated with statistically significant decreases in diastolic blood pressure at 1 h, 2 h, and 6 h post-dosing, with a maximum mean difference from placebo of -3.2 mmHg (90% CI -5.0, -1.4) at 6 h. The 50 mg/kg dose of deferiprone was associated with statistically significant decreases in diastolic blood pressure at 1 h, 2 h, and 4 h post-dosing, with a maximum mean difference from placebo of -4.5 mmHg (90% CI -6.4, -2.7) at 4 h.

10.3 Pharmacokinetics

Following administration of deferiprone 500 mg tablets at doses of 33 mg/kg and 50 mg/kg in healthy volunteers, mean maximum serum deferiprone concentrations were reached at approximately 0.8 h and then declined in a multi-exponential manner. Mean apparent terminal elimination half-life was approximately 1.8 h, and the AUC_{0-t} values were 93 and 148 µg·h/mL for the 33 mg/kg and 50 mg/kg doses, respectively (see Table 6 below).

Exposures to deferiprone and deferiprone 3-*O*-glucuronide were proportional to dose, i.e., approximately 60% higher following the 50 mg/kg deferiprone dose than after the 33 mg/kg dose. The PK parameter values of T_{max}, half-life, CL/F, and Vz/F were similar between the 2 treatments and doses.

Table 6: Mean (SD) Deferiprone and Glucuronide Serum Pharmacokinetic Parameters in Healthy Volunteers following a Single Dose of Deferiprone 500 mg tablets under Fasting Conditions

Pharmacokinetic Parameters	33 mg/kg (N=46)	50 mg/kg (N=48)
Deferiprone		
C _{max} (µg/mL)	34 (8.85)	54 (16.4)
T _{max} (h) ^a	0.82 (0.32, 2.13)	0.82 (0.57, 4.07)
AUC _{0-t} (µg·h/mL)	93 (17.4)	148 (22.1)
t _{1/2} (h)	1.85 (0.31)	1.84 (0.25)
CL/F (L/h)	25 (5.58)	23 (4.57)
V _z /F (L)	66 (15.4)	62 (14.9)

Deferiprone glucuronide		
C_{max} ($\mu\text{g/mL}$)	35 (8.54)	51 (13.4)
T_{max} (h) ^a	3.07 (1.39, 4.07)	3.07 (2.07, 6.07)
AUC_{0-t} ($\mu\text{g}\cdot\text{h/mL}$)	203 (44)	330 (75.2)
$t_{1/2}$ (h)	2.51 (0.52)	2.59 (0.24)

a. T_{max} is presented as Median (Minimum, Maximum)

Absorption

Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract, appearing in the blood within 5 to 10 minutes of oral administration. Exposures to deferiprone are dose proportional over the dose range of 22-50 mg/kg.

Pharmacokinetic data in patients with iron overload are limited. In four adult patients with iron overload and biopsy-proven liver cirrhosis, the mean C_{max} was 11 $\mu\text{g/mL}$ and AUC_{0-t} 33 $\mu\text{g}\cdot\text{h/mL}$ after a 25 mg/kg dose at steady state (25 mg/kg three times per day) following a standard breakfast. After an initial delay in absorption, deferiprone serum levels rose steadily to attain their maximum concentration at approximately 2 hours post-dose. In patients with iron overload, serum deferiprone levels are lower than in healthy subjects.

Food effect

Administration with food decreased the C_{max} of deferiprone by 38% and the AUC by 10%. Following a single dose of 33 mg/kg in healthy subjects under fasting conditions, the mean C_{max} was 35 $\mu\text{g/mL}$ and AUC_{0-t} 93 $\mu\text{g}\cdot\text{h/mL}$. Peak serum concentrations occurred approximately 1 hour after a single dose in fasted subjects, and up to 2 hours after a single dose in the fed state.

Distribution:

The volume of distribution of deferiprone is approximately 1 L/kg in healthy subjects and 1.6 L/kg in patients with iron overload. The *in vitro* plasma protein binding of deferiprone is approximately 14%.

At doses lower than those used clinically, deferiprone has been shown to penetrate the blood brain barrier in rats, and to interfere with dopamine and serotonin metabolism through inhibitory effects on catechol-O-methyltransferase and tyrosine and tryptophan hydroxylases.

Metabolism:

The majority of an oral dose of deferiprone is metabolized to deferiprone 3-O-glucuronide, which lacks iron binding capacity; *in vitro* evidence indicates that the conjugation is catalyzed primarily by UGT1A6. Peak serum concentration of the 3-O-glucuronide occurs approximately 3 to 4 hours after administration of deferiprone in healthy subjects and in patients with iron overload. Systemic exposure to deferiprone 3-O-glucuronide was 1.4- to 2-fold (on a molar basis) that of the parent drug in patients with iron overload.

Elimination

More than 90% of deferiprone is eliminated from plasma within 8 hours of ingestion. Following oral administration, 75% to 90% is recovered in the urine in the first 24 hours, primarily as the glucuronide, while approximately 5% of the administered dose is excreted as deferiprone. The elimination half-life is approximately 1.8 hours for deferiprone and 2.5 hours for the glucuronide metabolite in fasting healthy volunteers.

Special Populations and Conditions

The influence of age, race, gender, or obesity on deferiprone pharmacokinetics has not been established.

- **Pediatrics:** The pharmacokinetics of deferiprone in children was assessed in 7 patients with thalassemia and iron overload aged 11 to 18 years (mean age=15 ± 2.7 years; median=16 years). These patients were on long term therapy with deferiprone and were thus considered to be at steady state. Drug concentrations were measured following administration of a dose of deferiprone, 25 mg/kg, after a standard breakfast. The exposures to deferiprone of the pediatric patients were consistent with those determined in adult patients when the drug was administered under fed conditions. Serum levels of deferiprone were maximal approximately 2 hours after dosing and declined with a half-life of 1.8 hours; levels of deferiprone glucuronide peaked at approximately 3 hours and fell with a half-life of 2.0 hours. No pharmacokinetic study has been conducted in patients <11 years of age.
- **Hepatic Insufficiency:** The pharmacokinetics of deferiprone and its 3-*O*-glucuronide metabolite following a single oral 33 mg/kg dose of deferiprone 500 mg tablets were compared in subjects with mild (Child-Pugh classification score A: 5– 6 points) or moderate (Child-Pugh classification score B: 7– 9 points) hepatic impairment to healthy volunteers. Systemic exposure to deferiprone and to its metabolite deferiprone 3-*O*-glucuronide was assessed by the PK parameters C_{max} and AUC. AUC did not differ; C_{max} was decreased by 20% compared to healthy volunteers. The pharmacokinetic profile of deferiprone in patients with severe hepatic impairment has not been studied.
- **Renal Insufficiency:** The pharmacokinetics of deferiprone and its 3-*O*-glucuronide metabolite following a single oral 33 mg/kg dose of deferiprone 500 mg tablets were compared in subjects with renal impairment and in healthy volunteers. Systemic exposure to deferiprone, as indicated by C_{max} and AUC, was not significantly altered by renal impairment. Conversely, systemic exposure to the 3-*O*-glucuronide metabolite increased 1.3-, 2.7- and 5.6-fold (AUC_{∞}) in subjects with mild, moderate and severe renal impairment, respectively, as compared to that in subjects with normal renal function. Renal clearances of both deferiprone and the 3-*O*-glucuronide metabolite were significantly reduced by renal impairment. Most of the dose of deferiprone was excreted in urine over the first 24 hours as the 3-*O*-glucuronide metabolite, irrespective of the severity of renal impairment. The pharmacokinetic profile of deferiprone in patients with end-stage renal disease on dialysis has not been studied.

11. STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15 to 30°C).

Keep in a safe place out of the reach and sight of children.

12. SPECIAL HANDLING INSTRUCTIONS

None.

PART II: SCIENTIFIC INFORMATION

13. PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: deferiprone

Chemical name: 3-hydroxy-1,2-dimethylpyridin-4-one

Molecular formula and molecular mass: C₇H₉NO₂; 139.15 g/mol

Structural formula:



Physicochemical properties:

Solubility: deferiprone is slightly soluble in water and freely soluble in most polar organic solvents like methanol, ethanol and water at acidic pH (<3), practically insoluble in acetone

14. CLINICAL TRIALS

14.1 Clinical Trials by Indication

Transfusional iron overload due to Thalassemia syndromes

The efficacy of deferiprone for the treatment of patients with transfusional iron overload due to thalassemia syndromes has been evaluated in twelve clinical studies: eight clinical trials, one of which (LA16-0102) is considered pivotal, three compassionate use studies, and an investigator sponsored study. LA36-0310, a prospectively planned, pooled analysis of pre-existing data from these twelve studies, evaluated the efficacy of deferiprone in transfusion-dependent iron-overloaded patients (nearly all with thalassemia) in whom previous iron chelation therapy (deferioxamine or deferasirox; mostly deferioxamine) had failed, due to an inadequate response or poor tolerance.

Demographic characteristics for LA16-0102 and for LA36-0310 are shown in Table 7.

Table 7: Summary of patient demographics for clinical trials in Thalassemia syndromes

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
LA16-0102	Open-label, randomized, active comparator controlled clinical trial	Deferiprone: Initiated at a dose of 25 mg/kg <i>tid</i> for a total daily dose of 75 mg/kg. Treatment was increased to 28.3 mg/kg <i>tid</i> approximately 4 weeks after therapy initiation and further increased to the maintenance dose of 33.3 mg/kg <i>tid</i> for a total daily dose of 100 mg/kg approximately 8 weeks after therapy initiation. Deferoxamine: 50 mg/kg/day, subcutaneous infusion on 5-7 days per week. Duration: 12 months	Deferiprone = 29 Deferoxamine = 32	Deferiprone = 25.1 (18-32) Deferoxamine = 26.2 (18-35)	Deferiprone = 15 (52%) M/ 14 (48%) F Deferoxamine = 16 (50%) M / 16 (50%) F
LA36-0310	Prospectively planned, pooled analysis of pre-existing data	Deferiprone: 35 to 100 mg/kg/day, administered orally in either tablet or solution form. Duration: Up to 12 months	747	(monotherapy patients) For serum ferritin = 20 (2, 76) For LIC = 19 (6, 2) For MRI T2* = 25 (15, 32)	(monotherapy patients) For serum ferritin (236 patients) Female: 128 (54%) Male: 108 (46%) For LIC (87patients) Female: 45 (52%) Male: 42 (48%) For MRI T2* (31 patients ⁺) Female: 16 (52%) Male: 15 (48%)

⁺ 29 of 31 (93.5%) of the patients were from LA16-0102

LA16-0102

Study LA16-0102 was a 12-month, multi-centre, open-label, randomized, active controlled study conducted in transfusion-dependent β -thalassemia major patients between 18 and 36 years of age. Subjects had been receiving ongoing chelation therapy with deferoxamine for at least the past 5 years and had an abnormal (<20 milliseconds (ms)) but not severely abnormal (>8 ms) cardiac Magnetic Resonance Imaging T2-star (MRI T2*) value, a left ventricular ejection fraction (LVEF) greater than 56% (measured by Cardiovascular Magnetic Resonance), and a left ventricular shortening fraction greater than 30% (measured by echocardiogram). Patients were stratified into moderate (≥ 8 ms to <14 ms) or mild (≥ 14 ms to <20 ms) cardiac iron overload according to their baseline cardiac MRI T2* assessment and were randomized in a 1:1 ratio to receive either deferiprone administered three times a day (*tid*) orally in doses of 25 mg/kg for the first 4 weeks, increased to 28.3 mg/kg for the subsequent 4 weeks and maintained at 33.3 mg/kg for the remainder of the trial, or to continue with deferoxamine at a dose of 50 mg/kg/day administered by subcutaneous infusion on 5-7 days per week. A total of 61 patients were randomized and treated with deferiprone (N = 29) at an average dose of 92 mg/kg/day or with deferoxamine (N = 32) at an average dose of 43 mg/kg/day for 5.7 days per week.

The baseline demographics for age, sex, cardiac MRI T2* and liver iron concentration (LIC) were similar between the groups, although serum ferritin concentrations at baseline were higher in deferoxamine-treated patients (serum ferritin = 2,795 $\mu\text{g/L}$) compared to deferiprone-treated patients (serum ferritin = 1,790 $\mu\text{g/L}$). Deferiprone-treated patients had a mean baseline cardiac MRI T2* value of 13.6 ms and LIC of 6.16 mg Fe/g dry weight (mg/g dw); corresponding values in deferoxamine-treated patients were similar at 13.9 ms and 6.32 mg Fe/g dry weight, respectively.

The primary efficacy measure was the subjects' cardiac iron status as determined by cardiac MRI T2*. An increase in cardiac iron concentration will decrease the cardiac MRI T2* value. A cardiac T2* value below 20 ms demonstrates cardiac iron overload, and lower cardiac T2* values are observed with increased severity of overload. Secondary efficacy measures were the assessment of serum ferritin concentration and LIC. LIC was assessed by the Superconducting Quantum-Interference Device (SQUID) BioSusceptometer. A tertiary efficacy measure was the LVEF measured by Cardiovascular Magnetic Resonance.

At the 12-month assessment, there was an improvement in cardiac MRI T2* of 3.5 ms (from 13.0 ms to 16.5 ms) in patients treated with deferiprone compared with a change of 1.7 ms (from 13.3 ms to 15.0 ms) in patients treated with deferoxamine, which corresponds to 27% increase and 13% increase for deferiprone and deferoxamine, respectively. The improvement in cardiac MRI T2* was significantly greater for deferiprone than deferoxamine ($p = 0.02$).

No significant difference ($p = 0.16$) in mean change of serum ferritin from baseline to 12 months between the two treatment groups was detected. In addition, the difference in mean decrease in LIC at 12 months (0.61 mg/g dw) between the 2 groups was statistically non-significant ($p = 0.40$). Over the same 12 months, LVEF increased from baseline by 3.1 ± 3.6 absolute units (%) in the deferiprone group and by 0.3 ± 3.4 absolute units (%) in the deferoxamine group (difference between groups; nominal $p = 0.003$). Results for the efficacy endpoint MRI T2* are presented in Table 8. Results for efficacy endpoints serum ferritin, LIC and LVEF are presented in Table 9.

Table 8: LA16-0102: Relative Change in MRI T2* from baseline to 12 months for deferiprone and deferoxamine treatment groups – Intent-To-Treat Population

MRI T2*	Baseline		12 Months	
	Deferiprone [n=29]	Deferoxamine [n=32]	Deferiprone [n=29]	Deferoxamine [n=31]
Geometric Mean (milliseconds) [†]	13.0	13.3	16.5	15.0
Coefficient of Variation (%) [§]	32	30	38	39
Percentage of Baseline			127	113
Ratio of Means (%)	98		112	
p-value [¶]	0.77		0.02	

† Geometric mean is defined as antilog of the mean of the log data

§ Coefficient of variation is defined as $\sqrt{[e^{\text{variance}}-1]}$, where variance is the variance of the mean in log scale.

|| The ratio is defined as deferiprone mean/deferoxamine mean. At 12 months, the ratio is corrected for the difference in baseline mean between the two treatment groups by dividing it by 0.98.

¶ The Log (MRI T2*) between the deferiprone and deferoxamine treatment groups was compared by the two-sample t-test.

Table 9: LA16-0102: Change in other efficacy endpoints from baseline to 12 months for deferiprone and deferoxamine treatment groups – Intent-To-Treat Population

Parameter	Change from baseline to 12 months		Difference between two treatment groups (95% Confidence Interval)	P-value for the difference
	Deferiprone	Deferoxamine		
Mean (±SD) serum ferritin (µg/L) [N=number of study subjects]	-181 ± 826 (N=29)	-466 ± 739 (N=32)	285 (-116, 686)	0.16
Mean (±SD) LIC (mg/g dw) [N=number of study subjects]	-0.93 ± 2.93 (N=27)	-1.54 ± 2.49 (N=30)	0.61 (-0.83, 2.05)	0.40
Mean (±SD) LVEF (%) [N=number of study subjects]	3.07 ± 3.58 (N=29)	0.32 ± 3.38 (N=31)	2.75 (0.95, 4.55)	0.003

LA36-0310

In LA36-0310, data from 747 patients who had received deferiprone therapy were analyzed for study eligibility. Criteria for chelation failure were defined by one or more measures of iron

accumulation above a boundary level associated with an increased risk of organ damage, as follows: serum ferritin > 2,500 µg/L before treatment with deferiprone (main criterion); or liver iron concentration (LIC) of > 7 mg/g dw; or excess cardiac iron stores as demonstrated by a cardiac MRI T2* < 20 ms. Results from patients who received deferiprone in combination with other chelation therapy are excluded from the presented analysis. Analysis criteria were met for serum ferritin, LIC, and cardiac MRI T2* for 236 patients, and 87 patients, and 31 patients, respectively. Most (29/31 (93.5%)) of the patients evaluated for the cardiac MRI T2* criterion were from LA16-0102.

Deferiprone therapy was considered successful in individual patients who experienced a reduction in serum ferritin of ≥20% from baseline within one year of starting therapy (primary efficacy endpoint). Other success criteria (secondary efficacy endpoints) were a decline in LIC of ≥20% from baseline within one year of starting therapy or a decline in cardiac iron overload, defined as an increase in cardiac MRI T2* ≥20% from baseline within one year of starting therapy. Overall success rates were calculated as the proportion of patients with a successful outcome. In order to consider deferiprone therapy as successful for a particular measure, the lower limit of the 95% confidence interval (CI) for that efficacy measure had to be greater than 20%.

The dose of deferiprone ranged from 35-100 mg/kg/day, administered orally in either tablet or solution form. The majority (77%) of patients eligible for assessment for the primary efficacy endpoint were administered a dose of 75 mg/kg/day; 18% received a dose of 100 mg/kg/day and 5% received a dose of ≤ 50 mg/kg/day.

The success rate for serum ferritin for patients on deferiprone monotherapy was 50% (95% CI:43% to 57%). Mean serum ferritin decreased by 940 µg/L within one year of therapy (p=0.0001), i.e., from 4,444 µg/L at baseline to 3,503 µg/L at the last observation. The overall success rate for LIC was 38% (95% CI: 28% to 49%). For LIC, the mean decreased by 1.4 mg/g dw within one year of therapy (p=0.09), from 16.4 mg/g dw at baseline to 15.0 mg/g dw at the last observation. The overall success rate for cardiac MRI T2* was 65% (95% CI: 45% to 81%). For cardiac MRI T2* the mean increased by 3.9 ms within one year of therapy (p=0.0001), from 13.3 ms at baseline to 17.2 ms at the last observation.

Subgroup analyses were consistent with the primary analysis in that the lower limit of the 95% CI was greater than 20% for all subsets involved in analyses examining the impact of age, gender, and region.

Natural History Studies

Data from two natural history studies (Piga A, 2003; Borgna-Pignatti C, 2006) are supportive of the clinical effectiveness of deferiprone in the treatment of transfusional iron overload due to thalassemia syndromes.

Transfusional iron overload due to Sickle Cell Disease and Other Anemias

The efficacy of deferiprone for the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias has been evaluated in clinical trials LA38-0411 and LA38-EXT. A controlled non-inferiority study compared the efficacy of deferiprone to that of

deferoxamine in patients with sickle cell disease and other transfusion-dependent anemias by evaluating liver iron concentration.

Table 10: Summary of patient demographics for LA38-0411 in transfusional Iron Overload due to Sickle Cell Disease and Other Anemias

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
LA38-0411	Multi-center, randomized, open-label, active-controlled study comparing the efficacy and safety of deferiprone vs. deferoxamine in the population of interest	Deferiprone: 75 or 99 mg/kg/day Deferoxamine: 20 or 40 mg/kg/day, 5 to 7 days a week (children) 40 or 50 mg/kg/day, 5 to 7 days a week (adults) For up to 12 months	Deferiprone: 152 Deferoxamine: 76 Sickle Cell Anemia: 192 (84.2%) Other Anemias: 36 (15.8%)	16.9 (3-59)	Male: 121 (53.1%) Female: 107 (46.9%)

The primary endpoint was the change in liver iron concentration from baseline after 12 months of deferiprone (75 or 99 mg/kg/day) compared to deferoxamine (20 or 40 mg/kg (children); 40 or 50 mg/kg (adults)). Patient enrollment was stopped following an interim analysis. After adjusting for the type I (alpha) error, the non-inferiority criterion was established as the upper limit of the 96.01% confidence interval for the difference between treatments being ≤ 2 mg/g dry weight (dw).

Data from 185 patients (122 on deferiprone and 63 on deferoxamine) were analyzed. There were no significant treatment group differences at baseline or after 12 months (p -values >0.05). Over 12 months, the Least Squares estimate of mean decrease from baseline in liver iron concentration was 4.13 ± 0.50 mg/g dw for deferiprone and 4.38 ± 0.59 mg/g dw for deferoxamine, and the non-inferiority criterion was met.

Patients who completed the 1-year non-inferiority study LA38-0411 were offered the opportunity to take part in the 2-year extension study LA38-EXT. Those who had been treated with deferiprone continued to receive it (N=89), while those who had been treated with deferoxamine were switched to deferiprone (N=45). Liver iron concentration continued to decrease over time, with the mean value dropping from 14.93 mg/g dw at baseline to 12.30 mg/g dw after one year of treatment, to 11.19 mg/g dw after two years of treatment, and to 10.45 mg/g dw after three years of deferiprone treatment.

14.3 Comparative Bioavailability Studies

A randomized, single-dose (1 x 1000 mg), two-way crossover comparative bioavailability study of Taro- Deferiprone tablets 1000 mg (Taro Pharmaceuticals Inc.) with PrFERRIPROX tablets 1000 mg

(Chiesi Canada Corp.) was conducted in healthy, adult male subjects under fasting conditions. Comparative bioavailability data from 36 subjects that were included in the statistical analysis are presented in the following table:

Table 11. Summary Table of the Comparative Bioavailability Data

Deferiprone (1 x 1000 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
AUC _T (µg·h/mL)	33.5 35.3 (32.1)	33.5 35.0 (30.2)	100.2	97.6 - 102.8
AUC _I (µg·h/mL)	34.5 36.3 (31.7)	34.4 36.0 (29.9)	100.2	97.8 - 102.7
C _{max} (µg/mL)	13.5 14.6 (39.1)	12.9 13.5 (33.7)	104.7	92.8 - 118.2
T _{max} ³ (h)	0.67 (0.33 - 2.00)	0.50 (0.33 - 3.00)		
T _½ ⁴ (h)	1.82 (21.18)	1.74 (16.57)		

¹ Taro-Deferiprone (deferiprone) tablets, 1000 mg (Taro Pharmaceuticals Inc.)

² PrFERRIPROX (deferiprone) tablets, 1000 mg (Chiesi Canada Corp.)

³ Expressed as the median (range) only

⁴ Expressed as the arithmetic mean (CV%) only

15. MICROBIOLOGY

No microbiological information is required for this drug product.

16. NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity

The median lethal dose (LD₅₀) of deferiprone in non-iron-loaded mice and rats given a single i.p. injection was 983 and 650 mg/kg, respectively. Convulsions preceded death in mice. The oral LD₅₀ in rats was 2,000 to 3,000 mg/kg.

Subchronic and Long-Term Toxicity

In a 3-month rodent toxicology study, a minority of iron-supplemented rats given 125 mg/kg deferiprone *bid* orally were subject to unscheduled euthanasia during the latter two-thirds of the study, as a result of declining clinical condition, and decreased circulating RBC, platelet, and WBC counts. Microscopic examination revealed bone marrow hypocellularity, hepatic centrilobular

degeneration and necrosis, and lymphocytic depletion in the thymic cortex. Bone marrow depression and non-regenerative anemia were considered to be the cause of death. Less severe effects were evident at 75 mg/kg *bid*, but no toxicologically relevant effects occurred at 37.5 mg/kg *bid*.

In a 3-month primate toxicology study, non-iron-loaded monkeys were terminated because of declining physical condition after 42-50 days' oral administration of deferiprone, 125 mg/kg *bid* and later 150 mg/kg *bid*; animals given 50 or 100 mg/kg *bid* (100 or 200 mg/kg/day) survived treatment as scheduled. Moderate to severe reductions in circulating platelet, reticulocyte and white cell (all types) counts were observed. Serum levels of iron were also decreased. Intestinal degeneration and necrosis were identified as the cause of morbidity, but bone marrow hypocellularity, depletion and necrosis of thymus, spleen and lymph nodes, and liver pathology were also significant. No toxicologically relevant effects were noted at 50 mg/kg *bid*.

In a 12-month rodent toxicology study, following administration of deferiprone at doses of 150 or 200 mg/kg/day in 2 divided doses (75 or 100 mg/kg *bid*), to non-iron-loaded or iron-loaded rats, respectively, 7 of 50 non-iron-loaded and 3 of 50 iron-loaded animals were either found dead or sacrificed moribund with severe anemia and slight to moderate centrilobular degeneration and necrosis. Animals from which blood samples could be collected prior to their unscheduled termination had elevated levels of total bilirubin, aspartate aminotransferase, and/or alanine aminotransferase of up to ca. 8, 4, and 14 times their respective group mean control value. These findings could be ascribed to hypoxia due to severe anemia (hemoglobin concentration <2.5 g/dL). No findings of severe anemia with or without centrilobular degeneration and necrosis, or isolated findings of centrilobular degeneration and necrosis, were noted in non-iron-loaded or iron-loaded survivors. Relatively mild decreases in RBC and WBC counts in surviving rats partially reversed during a 4-week off-dose period following 12 months' treatment; recovery of bone marrow hypocellularity was complete in iron-loaded, but partial in non-iron-loaded, animals. The mean relative weight of the adrenal and pituitary gland was significantly greater in non-iron-loaded rats given 75 mg/kg deferiprone *bid* as compared to non-iron-loaded untreated rats.

In a 12-month primate toxicology study, no treatment-related changes were detected in non-iron-loaded monkeys dosed orally with 75 mg/kg deferiprone *bid*. Iron loading produced increases in serum ALT activity, which may have been exacerbated by deferiprone.

Carcinogenicity:

Non-clinical carcinogenicity studies have not been conducted with deferiprone. In a 12 month rat toxicology study, reversible mammary gland hyperplasia occurred in female animals of all deferiprone-treated groups, irrespective of iron loading. The incidence of mammary tumors (1 of 65 males, 1 of 65 females) in deferiprone-treated animals was not statistically significantly different from that in controls.

However, in view of positive genotoxicity results (refer to genotoxicity information below) and the findings of mammary gland hyperplasia and mammary gland tumors in rats treated with deferiprone for 52 weeks, tumor formation in rodent carcinogenicity studies must be regarded as

likely. Deferiprone was clastogenic in an *in vitro* mouse lymphoma cell assay and in a Chinese hamster ovary cell chromosomal aberration test. Deferiprone given orally or intraperitoneally was clastogenic in a bone marrow micronucleus assay in non-iron-loaded mice. A micronucleus test was also positive when mice predosed with iron dextran were treated with deferiprone.

Genotoxicity:

Deferiprone was not mutagenic in a bacterial reverse mutation assay. It was positive in an *in vitro* L5178Y/TK+/- mouse lymphoma mutagenesis assay in the absence or presence of metabolic activation. Evidence of clastogenic effect was observed in a bone marrow micronucleus test in non-iron-loaded mice and after iron loading. There was no difference in the frequencies of lymphocyte chromosomal aberrations in thalassemia patients treated with deferiprone and deferoxamine in a clinical trial conducted to a crossover design.

Reproductive and Developmental Toxicology:

Deferiprone had no significant effects on fertility and reproductive performance in non-iron-loaded male and female rats dosed orally at ≤ 75 mg/kg *bid* prior to and through mating (males) or through early gestation (females). In females, estrous cycle prolongation (manifested as time to confirmed mating) was noted at all doses tested.

Skeletal and soft tissue malformations occurred in offspring of rats and rabbits that received deferiprone orally during organogenesis at the lowest doses tested (25 mg/kg per day in rats; 10 mg/kg per day in rabbits). These doses were equivalent to 3% to 4% of the maximum recommended human dose (MRHD) based on body surface area. No maternal toxicity was evident at these doses.

Embryofetal lethality and maternal toxicity occurred in pregnant rabbits given 100 mg/kg/day deferiprone orally during the period of organogenesis. This dose is equivalent to 32% of the MRHD based on body surface area.

17. SUPPORTING PRODUCT MONOGRAPHS

1. FERRIPROX (deferiprone tablets, 500 mg and 1000 mg; deferiprone oral solution, 100 mg/mL) and FERRIPROX MR (deferiprone extended-release tablets, 1000 mg), Submission Control No. 261912, Product Monograph, Chiesi Canada Corp., March 29, 2023.

PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

P^rTaro-Deferiprone

Deferiprone Tablets

Read this carefully before you start taking **Taro-Deferiprone** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Taro-Deferiprone**.

Serious Warnings and Precautions

Taro-Deferiprone can cause a sudden severe drop in the neutrophil count. Some patients taking Taro-Deferiprone had a very low count of their neutrophils, a type of white blood cell that helps fight infections. This low count is called severe neutropenia or agranulocytosis. It can lead to a serious infection that can be deadly, if not treated.

Before you start Taro-Deferiprone your healthcare professional will order a blood test to check your neutrophil count. You will do this test every week while you are on Taro-Deferiprone. If your count is too low, this testing may need to be done every day until you recover.

If you develop signs of infection such as fever, chills, sore throat, mouth sores, or flu-like symptoms, **stop taking Taro-Deferiprone and get medical help right away.**

What is Taro-Deferiprone used for?

Taro-Deferiprone is used to treat iron overload (too much iron in the body) from blood transfusions in patients with:

- thalassemia syndromes. They are used when other iron removal medicines do not work well enough.
- sickle cell disease or other anemias.

How does Taro-Deferiprone work?

Deferiprone, the ingredient in Taro-Deferiprone, is in a class of medicines called iron chelators. It works by removing excess iron from the body. By doing this, it protects your body against toxic effects of iron.

What are the ingredients in Taro-Deferiprone?

Medicinal ingredient: deferiprone

Non-medicinal ingredients: methylcellulose, crospovidone type B, magnesium stearate, purified water, white film coating (hypromellose 2910, copovidone K25-31, polydextrose, macrogol/PEG 3350, medium chain triglycerides, titanium dioxide)

Taro-Deferiprone comes in the following dosage forms:

Tablets: 1000 mg

Do not use Taro-Deferiprone if:

- you are allergic to deferiprone or any of the ingredients in Taro-Deferiprone (see What are the ingredients in Taro-Deferiprone section above)
- you are pregnant or breast-feeding
- you have a very low neutrophil count. Your healthcare professional will only start you on Taro-Deferiprone if you have enough neutrophils.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Taro-Deferiprone. Talk about any health conditions or problems you may have, including if you have:

- liver problems
- hepatitis C
- a weak immune system
- low zinc in your blood. Taro-Deferiprone may cause low levels of zinc in your blood.
- ever had a low white blood cell count during past use of Taro-Deferiprone.

Other warnings you should know about:**Neutropenia:**

- If you get neutropenia, avoid contact with other people. This may help to lower the risk of infection.
- If you get a very low neutrophil count you may need to be treated in a hospital.
- Do not use Taro-Deferiprone if you have Diamond-Blackfan anemia. You may have a higher risk of neutropenia if treated with Taro-Deferiprone .

Wallet Card

You will receive a wallet card every time you get a shipment of Taro-Deferiprone. This card has important safety information about the serious side effects of Taro-Deferiprone that you and any other healthcare professional involved in your care should know.

- Carry this card with you at all times
- If you become ill or consult a healthcare professional for any reason:
 - Show the card to any healthcare professional you consult
 - Explain that the card has important information about the serious side effects of the medicine you take.

Cancer:

- Taro-Deferiprone is likely to cause cancer in rodents. Talk with your healthcare professional to learn more about this.

Children

- Children taking Taro-Deferiprone may have more certain side effects than adults.

These side effects include:

- belly, bone and throat pain
- low neutrophil count

Pregnancy, Breastfeeding and Fertility

If you are a **woman**:

Pregnancy and birth control:

- Taro-Deferiprone can harm an unborn baby.
- Do **not** take Taro-Deferiprone if you are pregnant
- If you are a woman on Taro-Deferiprone who may become pregnant:
 - do **not** get pregnant
 - use highly effective birth control during treatment with Taro-Deferiprone and for at least 6 months after the last dose. Talk with your healthcare professional about how to choose an effective birth control
 - If you become pregnant, **tell your healthcare professional right away.**
 - tell your healthcare professional if you plan to become pregnant.

Breastfeeding:

- It is possible that Taro-Deferiprone passes into breast milk.
- you must **not** breast-feed while you take Taro-Deferiprone
- If you want to breastfeed, discuss with your healthcare professional

If you are a **man**:

- if your partner can get pregnant, use highly effective birth control during treatment with Taro-Deferiprone tablets and for at least 3 months after the last dose. Talk to your healthcare professional about how to choose an effective birth control
- if your partner gets pregnant, **tell your healthcare professional right away**

Monitoring, laboratory and blood tests:

- Your healthcare professional may do blood tests before you take Taro-Deferiprone and/or during treatment. These tests may check:
 - the level of white blood cells in your body.
 - that your liver is working properly.
 - the iron or zinc levels in your blood.

- Taro-Deferiprone may cause problems with certain lab tests. Tell all of your healthcare professional that you take Taro-Deferiprone

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Taro-Deferiprone:

- other medicines that can decrease your neutrophil count
- antacids, multivitamins or mineral supplements that contain iron, aluminum, or zinc. Take them at least 4 hours before or 4 hours after you take Taro-Deferiprone.

How to take Taro-Deferiprone:

Take Taro-Deferiprone tablets:

- **3 times a day**
- with or without food. Taking Taro-Deferiprone with meals may help reduce nausea. If you have nausea, vomiting or abdominal pain, your healthcare professional may lower your dose for 1 to 2 weeks.
- If you are taking Taro-Deferiprone tablets and your dose includes taking half of a tablet, cut or break the tablet along the score line on the tablet

Usual dose:

Your healthcare professional will decide the right dose of Taro-Deferiprone. It will be based on how much you weigh.

Ask your healthcare professional if you are not sure. Do **not** change your dose or how often you take this medicine unless your healthcare professional tells you to.

Overdose:

If you think you, or a person you are caring for, have taken too much Taro-Deferiprone, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you forget a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and then continue with your regular schedule. Do not try to catch-up or take 2 doses at the same time to make up for a missed dose.

What are possible side effects from using Taro-Deferiprone?

These are not all the possible side effects you may have when taking Taro-Deferiprone. If you experience any side effects not listed here, tell your healthcare professional. Please also see Warnings and Precautions.

The most common side effects of Taro-Deferiprone include:

- belly pain, diarrhea, nausea, upset stomach, vomiting
- arm, back, bone, joint, or leg pain
- fever
- headache
- appetite too low or high, weight gain
- sore throat
- red or brown discoloration of your pee (urine). This is due to your body getting rid of iron. It is not harmful and is expected during treatment with Taro-Deferiprone
- Increase liver enzyme

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Neutropenia ((low neutrophil count, / agranulocytosis (severe neutropenia): Signs of Infection: Fever, chills, sore throat, mouth sores, flu-like symptoms			✓
Sickle cell anemia crisis (sickle shaped red blood cells lump together): pain in chest, abdomen, bones of spine, arms and legs.		✓	
Neurological Side Effects: shaking, walking problems, double vision, involuntary muscle contractions, problems with movement coordination.		✓	
UNKNOWN			
Allergic reactions: difficulty swallowing or breathing, wheezing, drop in blood pressure, feeling sick to your stomach and throwing up, hives or rash, swelling of the face, lips, tongue or throat			✓
Henoch-Schönlein purpura: reddish-purple spots that look like bruises especially on the buttocks, legs and feet; swollen and sore joints; belly pain, or bloody urine			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Thrombocytosis (higher than normal platelet counts in the blood): headache, chest pain , burning pain in hands or feet, nosebleeds, bruising, bleeding from your mouth or gums, bloody stool.		✓	
Heart problems <ul style="list-style-type: none"> • Atrial fibrillation (abnormal heart rhythm which is rapid and irregular): chest discomfort with unpleasant awareness of your heartbeat, faintness, shortness of breath, weakness • Heart failure (heart does not pump blood as well as it should): shortness of breath, fatigue and weakness, swelling in ankles, legs and feet, cough, fluid retention, lack of appetite, nausea, rapid or irregular heartbeat, reduced ability to exercise 			✓
Gastrointestinal (stomach or bowel) problems: <ul style="list-style-type: none"> • enterocolitis (serious problems of the intestines): pain, cramping, swelling or bloating in the belly, bloody stool, diarrhea, vomiting, fever • rectal bleeding (bleeding from your bottom (anus)). 			✓
Pancreatitis (inflammation of the pancreas): upper abdominal pain, fever, rapid heartbeat, nausea, vomiting, tenderness when touching the abdomen		✓	
Cerebral hemorrhage (bleeding in the brain): sudden, severe headache; confusion; nausea and vomiting;			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
seizures; loss of consciousness			
Depression (sad mood that won't go away): difficulty sleeping or sleeping too much, changes in appetite or weight, feelings of worthlessness, guilt, regret, helplessness or hopelessness, withdrawal from social situations, family, gatherings and activities with friends, reduced libido (sex drive) and thoughts of death or suicide. If you have a history of depression, your depression may become worse		✓	
Obsessive-compulsive disorder repeated, persistent and unwanted thoughts, behaviours such as hand washing/cleaning, checking on things that may interfere with daily activities and cause distress or anxiety		✓	
Acute Respiratory Distress Syndrome (ARDS): severe difficulty breathing, including shortness of breath at rest or with activity, rapid breathing, wheezing or cough			✓
Pulmonary embolism (blood clot in the lung): chest pain that may increase with deep breathing, cough, coughing up bloody sputum, shortness of breath			✓
Hemoptysis: coughing up blood			✓
Sepsis and septic shock (infection of the blood): fever or dizziness, chills, high or very low body temperature, little or no urine, low blood pressure, palpitations, rapid breathing, rapid heartbeat			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Multi-organ Dysfunction Syndrome (failure of multiple organs): failure of multiple organs (e.g. lung, kidney, heart) at the same time including passing less urine, difficulty breathing (including shortness of breath at rest or with activity), rapid breathing, wheezing or cough; yellowing of your skin and eyes, stomach pain or swelling, nausea or vomiting; chest pain (angina), shortness of breath, rapid, strong or irregular heartbeat, or if there is swelling of your ankles and feet			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Do not use Taro-Deferiprone after the expiry date, which is stated on the package after EXP.

Keep out of reach and sight of children.

Store at room temperature (15 to 30°C).

Taro Cares

Taro-Deferiprone is only available through the program **Taro Cares**. The program will help manage the risk of low white blood cell counts in patients taking Taro-Deferiprone.

DOCTOR

Only doctors registered in the program can prescribe Taro-Deferiprone.

PHARMACIST

Only pharmacists registered in the program can dispense Taro-Deferiprone. They do this by shipping the medication to you. In each shipment, you will receive:

- Wallet card
- A month supply of Taro-Deferiprone. The tablets may be sent to you:
 - in the bottle produced by the manufacturer
 - in a bottle prepared by the pharmacist
 - you may get a combination of these.
- Patient Medication Information
 - may come on loose printed papers
 - may be attached to the manufacturer's bottle
 - if there are changes to this information, you will receive information on a separate sheet. The sheet will be in a different colour.

If you need to talk to the pharmacist call 1-800-268-1975 or log onto www.taro.ca. You can only receive drug counselling by phone.

PATIENT

Taro-Deferiprone can only be dispensed to patients enrolled in **Taro Cares**. If you need more Taro-Deferiprone for any reason such as travel, spills or lost tablets, call 1-800-268-1975 or log onto tarocares.ca. Resupply is arranged on a case by case basis.

For more information on Taro-Deferiprone please call 1-800-268-1975 or log onto www.taro.ca.

If you want more information about Taro-Deferiprone:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (www.taro.ca), or by calling 1-800-268-1975.

This leaflet was prepared by Taro Pharmaceuticals Inc.

Last Revised: NOV 13, 2024